Gpr182-mediated calcium mobilization is required for definitive hematopoiesis

Gpr182 介导的钙动员是最终造血所必需的

基本信息

项目摘要

Abstract Hematopoietic stem cells (HSCs) are self-renewing cells that produce all major blood cell lineages during an individual’s lifetime. During embryonic specification of HSCs, axial vasculature must be appropriately patterned; vascular endothelial cells of the embryonic aorta can be broadly categorized into hemogenic endothelium (HE) and non-hemogenic endothelium. HSCs transdifferentiate specifically from HE and enter circulation. It has long been understood that proper tissue patterning and transcriptional regulation are required for adequate specification and production of HSCs. More recently, it has become clear that cell populations surrounding the sites of HSC development—known as the HSC microenvironment—provide inductive signaling cues that are required for HSC specification. Signaling molecules established in HSC specification, such as Wingless (Wnt) and Hedgehog (Hh), activate G protein-coupled receptor (GPCR)-driven signaling pathways in endothelial cells. Our lab has demonstrated that Gpr182, an endothelial GPCR without a currently known ligand, regulates intracellular Ca2+ mobilization during the time of HSC specification. Transient loss of Gpr182 leads to a reduction in HSC precursors. These data suggest that a Gpr182-induced increase in calcium levels may be required for HSC specification. Our lab has also shown that pharmacological inhibition of the calcium sensor and effector proteins calmodulin and calcineurin disrupts HSC specification. The nuclear factor of activated T cells (NFAT) family of transcription factors act downstream of calcineurin. Several NFAT family members are expressed at the right time and place to potentially influence HSC specification in the zebrafish model. However, it is unknown whether or how these transcription factors HSC specification. While in vitro data have shown a connection between Gpr182 expression and NFAT response element activity, no connection between these two molecules has been made in vivo. I hypothesize that Gpr182-mediated activation of the Ca2+-calcineurin-NFAT signaling axis is required for HSC specification. To test this hypothesis, I will first evaluate the role of Gpr182 activity in Ca2+ mobilization and HSC specification by defining that Gpr182 is required for HSC specification, evaluating the effects of gpr182 gene knockout on Ca2+ mobilization, assessing the contribution of Gpr182 candidate co-receptor Ramp2 to endothelial Ca2+ mobilization, and determining if Gpr182 functions cell- autonomously in HSC precursors. Second, I will determine if NFAT transcription factors are required for HSC specification through performing loss-of-function genetic studies with morpholino oligonucleotides, generating stable mutant knockout zebrafish, and assessing the potential for constitutively active NFAT to rescue hematopoietic defects caused by Gpr182 loss-of-function. These studies will advance the field of developmental hematopoiesis by establishing a previously unknown role for Ca2+ mobilization and NFAT activity in HSC specification. These findings will better inform efforts of reprogramming HSCs from induced pluripotent stem cells (iPSCs), which has been a longstanding goal of regenerative medicine.
摘要 造血干细胞(HSC)是自我更新的细胞,其在发育过程中产生所有主要的血细胞谱系。 个人的一生。在HSC的胚胎特化过程中,轴向血管必须适当地形成; 胚胎主动脉的血管内皮细胞可大致分为生血内皮细胞(HE), 和非生血内皮。HSC特异性地从HE转分化并进入循环。长期 已经理解,适当的组织图案化和转录调控是足够的 HSC的规格和生产。最近,人们已经清楚地看到,细胞周围的细胞群, HSC发育的位点--称为HSC微环境--提供了诱导性信号线索, HSC规范要求。在HSC特化中建立的信号分子,如Wingless(Wnt) 和Hedgehog(Hh),激活内皮细胞中G蛋白偶联受体(GPCR)驱动的信号通路。 我们的实验室已经证明,Gpr 182,一种没有目前已知配体的内皮GPCR, 在HSC特化期间细胞内Ca 2+动员。Gpr 182的瞬时损失导致 HSC的前体。这些数据表明,可能需要Gpr 182诱导的钙水平增加, HSC规格。我们的实验室还表明,药物抑制钙传感器和效应器, 蛋白质钙调蛋白和钙调磷酸酶破坏HSC特化。活化T细胞核因子(NFAT) 转录因子家族在钙调磷酸酶下游起作用。几个NFAT家族成员表达于 合适的时间和地点可能影响斑马鱼模型中的HSC规格。但不清楚 这些转录因子是否或如何特异化HSC。虽然体外数据显示 Gpr 182表达和NFAT反应元件活性之间,这两种分子之间没有联系 是在体内制造的。我假设Gpr 182介导的Ca 2 +-钙调神经磷酸酶-NFAT的激活 信令轴是HSC规范所必需的。为了验证这一假设,我将首先评估Gpr 182的作用。 通过定义Gpr 182是HSC特化所需的, 评价gpr 182基因敲除对Ca 2+动员的影响, 候选共受体Ramp 2对内皮Ca 2+动员的作用,并确定Gpr 182是否在细胞内起作用。 在HSC前体中自主地。其次,我将确定NFAT转录因子是否是HSC所必需的。 通过用吗啉代寡核苷酸进行功能丧失遗传学研究, 稳定的突变敲除斑马鱼,并评估组成型活性NFAT拯救 由Gpr 182功能丧失引起的造血缺陷。这些研究将推动发展领域 通过建立HSC中Ca 2+动员和NFAT活性的先前未知作用来促进造血 规范.这些发现将更好地为从诱导多能干细胞重编程HSC的努力提供信息。 细胞(iPSC),这一直是再生医学的长期目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

McLean H Williamson其他文献

McLean H Williamson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('McLean H Williamson', 18)}}的其他基金

Gpr182-mediated calcium mobilization is required for definitive hematopoiesis
Gpr182 介导的钙动员是最终造血所必需的
  • 批准号:
    10687007
  • 财政年份:
    2021
  • 资助金额:
    $ 4.2万
  • 项目类别:
Gpr182-mediated calcium mobilization is required for definitive hematopoiesis
Gpr182 介导的钙动员是最终造血所必需的
  • 批准号:
    10669551
  • 财政年份:
    2021
  • 资助金额:
    $ 4.2万
  • 项目类别:

相似国自然基金

PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
  • 批准号:
    82372275
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
基于NLRP3/IL-1β信号探讨α7nAChR介导巨噬细胞—心肌细胞互作在Aβ诱导房颤心房重构中的作用及机制研究
  • 批准号:
    82300356
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
Tom1L1在胞内体蛋白分选机制中功能的研究
  • 批准号:
    31171289
  • 批准年份:
    2011
  • 资助金额:
    56.0 万元
  • 项目类别:
    面上项目
溶酶体依赖性TRAF2降解的机制
  • 批准号:
    30971501
  • 批准年份:
    2009
  • 资助金额:
    31.0 万元
  • 项目类别:
    面上项目

相似海外基金

Frontocortical representations of amygdala-mediated learning under uncertainty
不确定性下杏仁核介导的学习的额皮质表征
  • 批准号:
    10825354
  • 财政年份:
    2024
  • 资助金额:
    $ 4.2万
  • 项目类别:
Noradrenergic gating of astrocyte calcium-mediated homeostasis in vivo
星形胶质细胞钙介导体内稳态的去甲肾上腺素能门控
  • 批准号:
    10679269
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Develop an engineered Cas effector for in vivo cell-targeted delivery in the eye to treat autosomal dominant BEST disease
开发工程化 Cas 效应器,用于眼内体内细胞靶向递送,以治疗常染色体显性 BEST 疾病
  • 批准号:
    10668167
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Salt Mediated Cross Talk Between Lymphatic Vessels and Immune Cells in Kidney Disease
盐介导肾脏疾病中淋巴管和免疫细胞之间的交互作用
  • 批准号:
    10636755
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Isolating region specific α-syn-mediated mechanisms in mitochondrial function in vivo
体内线粒体功能中分离区域特异性 α-syn 介导的机制
  • 批准号:
    10809994
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Role of RNA helicase Ddx5 in pathological cardiac remodeling
RNA解旋酶Ddx5在病理性心脏重塑中的作用
  • 批准号:
    10718560
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Carbohydrate-Mediated Platelet Clearance
碳水化合物介导的血小板清除
  • 批准号:
    10608645
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Molecular mechanisms of load-induced t-tubule regulation in the mammalian heart
哺乳动物心脏负荷诱导 T 管调节的分子机制
  • 批准号:
    10664338
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
Pathogenic hotspots illuminate mechanism and therapeutic potential in arrhythmogenic cardiomyopathy
致病热点阐明致心律失常性心肌病的机制和治疗潜力
  • 批准号:
    10633507
  • 财政年份:
    2023
  • 资助金额:
    $ 4.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了